Efficacy and safety of recombinant human activated protein C for severe sepsis

BACKGROUND Drotrecogin alfa (activated), or recombinant human activated protein C, has antithrombotic, antiinflammatory, and profibrinolytic properties. In a previous study, drotrecogin alfa activated produced dose-dependent reductions in the levels of markers of coagulation and inflammation in patients with severe sepsis. In this phase 3 trial, we assessed whether treatment with drotrecogin alfa activated reduced the rate of death from any cause among patients with severe sepsis. METHODS We conducted a randomized, double-blind, placebo-controlled, multicenter trial. Patients with systemic inflammation and organ failure due to acute infection were enrolled and assigned to receive an intravenous infusion of either placebo or drotrecogin alfa activated (24 microg per kilogram of body weight per hour) for a total duration of 96 hours. The prospectively defined primary end point was death from any cause and was assessed 28 days after the start of the infusion. Patients were monitored for adverse events; changes in vital signs, laboratory variables, and the results of microbiologic cultures; and the development of neutralizing antibodies against activated protein C. RESULTS A total of 1690 randomized patients were treated (840 in the placebo group and 850 in the drotrecogin alfa activated group). The mortality rate was 30.8 percent in the placebo group and 24.7 percent in the drotrecogin alfa activated group. On the basis of the prospectively defined primary analysis, treatment with drotrecogin alfa activated was associated with a reduction in the relative risk of death of 19.4 percent (95 percent confidence interval, 6.6 to 30.5) and an absolute reduction in the risk of death of 6.1 percent (P=0.005). The incidence of serious bleeding was higher in the drotrecogin alfa activated group than in the placebo group (3.5 percent vs. 2.0 percent, P=0.06). CONCLUSIONS Treatment with drotrecogin alfa activated significantly reduces mortality in patients with severe sepsis and may be associated with an increased risk of bleeding.

[1]  T. Iba,et al.  [Disseminated intravascular coagulation]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.

[2]  Adam L. Cohen.  The pharmaceutical industry as an informant , 2003, The Lancet.

[3]  M. Büchler,et al.  Scientific Data from Clinical Trials: Investigators’ Responsibilities and Rights , 2002, Digestive Surgery.

[4]  H. Okabe,et al.  Activated Protein C Reduces the Ischemia/Reperfusion-Induced Spinal Cord Injury in Rats by Inhibiting Neutrophil Activation , 2000, Annals of surgery.

[5]  M. Angell.  Is academic medicine for sale? , 2000, The New England journal of medicine.

[6]  J. A. Kruse,et al.  E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. , 2000, JAMA.

[7]  D. Annane,et al.  A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. , 2000, JAMA.

[8]  J. Boldt,et al.  Changes of the hemostatic network in critically ill patients‐Is there a difference between sepsis, trauma, and neurosurgery patients? , 2000, Critical care medicine.

[9]  T. Iba,et al.  The role of the endothelium in changes in procoagulant activity in sepsis. , 1998, Journal of the American College of Surgeons.

[10]  M. Boffa,et al.  Thrombin, Thrombomodulin and TAFI in the Molecular Link Between Coagulation and Fibrinolysis , 1997, Thrombosis and Haemostasis.

[11]  R. Bone,et al.  Sepsis: a new hypothesis for pathogenesis of the disease process. , 1997, Chest.

[12]  T. van der Poll,et al.  Interleukin-6 Stimulates Coagulation, not Fibrinolysis, in Humans , 1996, Thrombosis and Haemostasis.

[13]  M. Nesheim,et al.  The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. , 1996, Blood.

[14]  D. Pittet,et al.  The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. , 1995, JAMA.

[15]  S. Grey,et al.  Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. , 1994, Journal of immunology.

[16]  B. Grinnell,et al.  Recombinant human protein C, protein S and thrombomodulin as antithrombotics , 1994 .

[17]  R. Hermann,et al.  Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide. , 1994, Glycobiology.

[18]  D. Powars,et al.  Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  J. Lorente,et al.  clinical investigations in critical care Time Course of Hemostatic Abnormalities in Sepsis and its Relation to Outcome * , 2006 .

[20]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[21]  C. Chopin,et al.  Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. , 1992, Chest.

[22]  C. Esmon.  The protein C anticoagulant pathway. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[23]  C. Esmon,et al.  Inflammation and Coagulation: Linked Processes Potentially Regulated Through a Common Pathway Mediated by Protein C , 1991, Thrombosis and Haemostasis.

[24]  D. Mcclure,et al.  Characterization and Novel Purification of Recombinant Human Protein C from Three Mammalian Cell Lines , 1990, Bio/Technology.

[25]  J. Weinberg,et al.  Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. , 1988, Blood.

[26]  A. Chang,et al.  Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. , 1987, The Journal of clinical investigation.

[27]  W. Fiers,et al.  Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[29]  J. Griffin,et al.  Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. , 1984, Blood.

[30]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[31]  C. Esmon,et al.  The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V. , 1979, Biochimica et biophysica acta.

[32]  J. Staropoli.  MSJAMA: Funding and practice of biomedical research. , 2003, Journal of the American Medical Association (JAMA).

[33]  G. Clermont,et al.  AGE-SPECIFIC INCIDENCE AND OUTCOME OF SEPSIS IN THE US , 1999 .

[34]  M. Vervloet,et al.  Derangements of Coagulation and Fibrinolysis in Critically III Patients with Sepsis and Septic Shock , 1998, Seminars in thrombosis and hemostasis.

[35]  U. Raeth,et al.  Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. , 1996, Immunology.

[36]  Increase in National Hospital Discharge Survey rates for septicemia--United States, 1979-1987. , 1990, MMWR. Morbidity and mortality weekly report.